Philip Ron M reported grant involving 1,109 derivative units of Avalo Therapeutics, Inc. at $12.29 for $13.6k on Sep 30, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Oct 2, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$13,629.61Shares × reported price
Shares traded
1,109Stock Option (Right to Buy)
Price per share
$12.29Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
1,109Direct
Trade date
Sep 30, 2026Grant
Filed
Oct 2, 2026, 4:15 PM ET2-day reporting delay
Accession
0002063957-26-000009Code A · Transaction 234604
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

AVTX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
AVTX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +29%1w ago +2.1%1d ago +3.9%
Returns since7d −8.9%30d −52%90d180d1y

Footnotes in full

F1: The options were granted on September 30, 2026, and are 100% vested. F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.